Polypharmacy in elderly patients Appropriateness of medication Medication therapy safety
Conditions
Interventions
Group 1: Patients make use of the software-supported medication review service in community pharmacies under routine conditions. Pharmacists analyse all drugs of a patient’s medication regimen for dru
Sponsors
Viandar GmbH
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: - age = 65 years - permanent intake of = 5 active pharmaceutical substances with systemic effects (combinations of active ingredients in phytotherapeutics and homeopathics are counted as a single active substance) - written informed consent - completed software-assisted medication review
Exclusion criteria
Exclusion criteria: - For patients with more than one completed medication review in the recruitment period, only the first analysis will be considered. - The inclusion of patients per pharmacy is limited to a maximum of 15% of the calculated samplze size (n = 148), which corresponds to 22 patients per pharmacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Appropriateness of medication at t0 (before medication examination) and at t2 (final medication (determined by physician)) measured using a modified version of the Medication Appropriateness Index (MAI) (Hanlon, 1992) Modifications: - Scoring weight of item on indication = „1“ point (instead of „3“) - Omission of item on cost-effectiveness | — |
Secondary
| Measure | Time frame |
|---|---|
| - Medication appropriateness at t0 (before conducting medication examination) and at t1 (pharmacist's recommended medication after conducting medication examination) measured by means of a modified version of the Medication Appropriateness Index (MAI) (Hanlon, 1992) - Medication underuse at t0, t1, t2 measured by means of the Assessment of Underutilization of Medication (AOU) (Jeffrey 1999, Hanlon 2001) - Exposure to anticholinergic/sedative drugs at t0, t1, t2 measured by means of the Drug Burden Index (DBI) (Hilmer, 2007) - Number of drugs used at t0, t1, t2 - Proportion of recommendations for medication adjustments accepted by physicians - Symptom burden at t0 and t3 (follow-up) measured by means of a self-developed instrument - Medication-related quality of life at t0 and t3 measured by means of an item created by Seidling et al. (2021) - Adherence at t0 and t3 measured by means of the Self-Rating Scale Item (SRSI) (Lu, 2008), modified - Achievement of patient-reported and health-related goals at t0 and t3 measured by means of a self-developed instrument - Perception of the intervention at t3 measured by means of a self-developed instrument | — |
Countries
Germany
Contacts
Public ContactStefan Maierhöfer
Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster
Outcome results
None listed